This morning we watched Sanofi ADS rise 4.9% to a price of $44.44 per share. The Large-Cap Pharmaceutical company is now trading -20.51% below its average target price of $55.9. Analysts have set target prices ranging from $51.0 to $63.0 per share for Sanofi ADS, and have given the stock an average rating of buy.
The stock has a very low short interest at 0.3%, and a short ratio of 2.32. At 0.0%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 8.9% of Sanofi ADS's shares being owned by this investor type.
Institutions Invested in Sanofi ADS
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2026-03-31 | Dodge & Cox Inc. | 11% | 29,504,632 | $1,311,038,363 |
| 2026-03-31 | Morgan Stanley | 5% | 12,511,867 | $555,964,827 |
| 2026-03-31 | Fisher Asset Management, LLC | 4% | 11,442,163 | $508,432,528 |
| 2026-03-31 | Bank of America Corporation | 4% | 9,484,350 | $421,437,105 |
| 2026-03-31 | Franklin Resources, Inc. | 3% | 7,165,193 | $318,385,360 |
| 2026-03-31 | Invesco Ltd. | 2% | 6,621,539 | $294,228,094 |
| 2026-03-31 | Barrow, Hanley Mewhinney & Strauss, LLC | 2% | 5,887,466 | $261,609,559 |
| 2026-03-31 | JPMORGAN CHASE & CO | 2% | 5,600,731 | $248,868,489 |
| 2026-03-31 | Mondrian Investment Partners Ltd | 2% | 5,040,065 | $223,955,295 |
| 2026-03-31 | Federated Hermes, Inc. | 2% | 4,754,359 | $211,259,948 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Sanofi ADS.
